Overview

Cross-over Study to Investigate Retinal Function Following Administration of a Single Dose of AZD9056

Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether treatment with a single 800mg dose of AZD9056, a medication which has been developed as a possible treatment for Rheumatoid Arthritis, has an effect on the function of the retina
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca